医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

 JEOL: Release of the New Scanning Electron Microscope JSM-IT700HR

2020年08月03日 PM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new scanning electron microscope (SEM), the JSM-IT700HR for unprecedentedly high throughput in August 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005011/en/

Note: The photo of the instrument is JSM-IT700HR/LA. (Photo: Business Wire)

Note: The photo of the instrument is JSM-IT700HR/LA. (Photo: Business Wire)

Development background

Scanning electron microscopes are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. In addition, SEM applications are expanding to include quality control as well as basic research. The demands are increasing for faster data acquisition of higher-quality SEM images and for easier confirmation of compositional information.

Based on our award-winning predecessor of “InTouchScope™” series SEMs, the JSM-IT700HR is equipped with our in-lens Schottky field emission electron gun (FEG). This new powerful SEM satisfies the needs for observation and analysis of further miniaturized materials in daily laboratory operation.

The JSM-IT700HR delivers a high resolution of 1 nm and a maximum probe current of 300 nA (15 times higher than previously), providing a wealth of observation and analysis information. A simple-to-operate user interface, the compact design accommodating a large specimen chamber, with a renewed anti-vibrational support for the main console achieve more comfortable observation and analysis than before.

For enhancing “Simple operation,” the JSM-IT700HR incorporates a new function, integrated into the SEM GUI, to display the characteristic X-ray generation depth. This supports prompt understanding of the analysis depth (reference) for the specimen, which is useful for elemental analysis.

2 configurations are available, 1) JSM-IT700HR/LV for high and low vacuum image observation, 2) JSM-IT700HR/LA with additional integrated JEOL EDS system.

Features

  1. The in-lens Schottky field emission electron gun allows for high-definition image observation and high spatial-resolution analysis.
  2. The Zeromag function, which links Holder Graphics, CCD and SEM images, makes specimen navigation easier than ever.
  3. With our “Analytical series” (Live Analysis function), the embedded EDS system shows a real-time EDS spectrum during image observation for efficient elemental analysis.
  4. A new function to display the analysis depth (characteristic X-ray generation depth) supports fast elemental analysis.
  5. SMILE VIEW™ Lab, enabling integrated management of image and analysis data, facilitates report generation for all data from collected SEM images to elemental analysis results.
  6. “Specimen Exchange Navi” enables safe and simple specimen exchange.
  7. With the Auto Beam Alignment function, the electron optical conditions are always kept optimum.
  8. “Drawout exchange system” allows easy access to the large specimen chamber, which accommodates various sizes and types of specimens

Sales target

130 units/year (initial year)

URL: https://www.jeol.co.jp/en/products/detail/JSM-IT700HR.html

JEOL Ltd.

3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & COO
(Stock code: 6951, Tokyo Stock Exchange First Section)
www.jeol.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005011/en/

CONTACT

JEOL Ltd.

Science and Measurement Instruments Sales Division

Yoshiki YAMASAKI

+81-3-6262-3567

https://www.jeol.co.jp/en/support/support_system/contact_products.html

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アジア太平洋地域での成長計画を促進すべくHumanigen Australia Proprietary Limitedを設立
  • MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ
  • COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries
  • Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
  • Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59